These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 24373107)
1. COX-2 inhibition: what we learned--a controversial update on safety data. Katz JA Pain Med; 2013 Dec; 14 Suppl 1():S29-34. PubMed ID: 24373107 [TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis. Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070 [TBL] [Abstract][Full Text] [Related]
3. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines. Price-Forbes AN; Callaghan R; Allen ME; Rowe IF Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035 [TBL] [Abstract][Full Text] [Related]
4. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man. Dajani EZ; Islam K J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633 [TBL] [Abstract][Full Text] [Related]
5. The COX-2 inhibitor market withdrawals and prescribing patterns by rheumatologists in patients with gastrointestinal and cardiovascular risk. Greenberg JD; Fisher MC; Kremer J; Chang H; Rosenstein ED; Kishimoto M; Lee S; Yazici Y; Kavanaugh A; Abramson SB; Clin Exp Rheumatol; 2009; 27(3):395-401. PubMed ID: 19604430 [TBL] [Abstract][Full Text] [Related]
6. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance. Borer JS; Simon LS Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S14-22. PubMed ID: 16168077 [TBL] [Abstract][Full Text] [Related]
7. COX-2 inhibitors: a CLASS act or Just VIGORously promoted. Malhotra S; Shafiq N; Pandhi P MedGenMed; 2004 Mar; 6(1):6. PubMed ID: 15208519 [TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase-2 inhibitors: what went wrong? James MJ; Cleland LG Curr Opin Clin Nutr Metab Care; 2006 Mar; 9(2):89-94. PubMed ID: 16477171 [TBL] [Abstract][Full Text] [Related]
9. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Scheiman JM; Hindley CE Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236 [TBL] [Abstract][Full Text] [Related]
10. Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs. Joshi GP; Gertler R; Fricker R Anesth Analg; 2007 Dec; 105(6):1793-804, table of contents. PubMed ID: 18042885 [TBL] [Abstract][Full Text] [Related]
11. [Cardiovascular and gastrointestinal risks associated with selective and non-selective NSAIDs]. van den Bemt BJ; Benraad HB; Rasker JJ Ned Tijdschr Geneeskd; 2007 May; 151(19):1062-7. PubMed ID: 17552414 [TBL] [Abstract][Full Text] [Related]
13. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis. Wang X; Tian HJ; Yang HK; Wanyan P; Peng YJ Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):876-80. PubMed ID: 21900785 [TBL] [Abstract][Full Text] [Related]
14. Cardiovascular issues of COX-2 inhibitors and NSAIDs. Wong M; Chowienczyk P; Kirkham B Aust Fam Physician; 2005 Nov; 34(11):945-8. PubMed ID: 16299629 [TBL] [Abstract][Full Text] [Related]
15. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs. Hur C; Chan AT; Tramontano AC; Gazelle GS Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709 [TBL] [Abstract][Full Text] [Related]
16. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs. van der Linden MW; van der Bij S; Welsing P; Kuipers EJ; Herings RM Ann Rheum Dis; 2009 May; 68(5):668-73. PubMed ID: 18495734 [TBL] [Abstract][Full Text] [Related]
18. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966 [TBL] [Abstract][Full Text] [Related]
19. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Farkouh ME; Greenberg BP Am J Cardiol; 2009 May; 103(9):1227-37. PubMed ID: 19406264 [TBL] [Abstract][Full Text] [Related]
20. The use of NSAIDs in rheumatic disorders 2005: a global perspective. Kean WF; Buchanan WW Inflammopharmacology; 2005; 13(4):343-70. PubMed ID: 16354389 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]